Business UpdateNov 5, 2026, 09:16 AM
AIM ImmunoTech Highlights Ampligen Opportunity in Pancreatic Cancer
AI Summary
AIM ImmunoTech Inc. has released a new investor presentation, "The Ampligen Opportunity," detailing the potential of its drug Ampligen (rintatolimod) to enhance emerging RAS-targeted therapies for pancreatic cancer, specifically in combination with Revolution Medicines' daraxonrasib. The presentation outlines the scientific rationale, previously reported clinical observations, and upcoming milestones for the Phase 2 DURIPANC program, with topline results expected in Q1 2027 and further analyses in Q3 2027. The company believes Ampligen's immune-stimulating properties could complement daraxonrasib's targeted inhibition to potentially prolong clinical benefit.
Key Highlights
- AIM ImmunoTech highlights Ampligen's potential to complement RAS-targeted therapies in pancreatic cancer.
- New investor presentation outlines scientific rationale for combining Ampligen with daraxonrasib.
- Phase 2 DURIPANC topline results expected in Q1 2027.
- Additional clinical and immune-response analyses from DURIPANC anticipated in Q3 2027.
- Daraxonrasib Phase 3 study showed median overall survival of 13.2 months vs. 6.7 months with chemotherapy.
- Named Patient Program showed median overall survival of 19.7 months for Ampligen-treated patients vs. 12.5 months for historical controls.
Price Impact
More from AIM